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Abstract: Patients with HIV-1 often present with a wide
range of hematopoietic abnormalities, some of which may
be due to the presence of opportunistic infections and to
therapeutic drug treatments. However, many of these
abnormalities are directly related to HIV-1 replication in
the bone marrow (BM). Although the most primitive
hematopoietic progenitor cells (HPCs) are resistant to HIV-
1 infection, once these cells begin to differentiate and
become committed HPCs they become increasingly
susceptible to HIV-1 infection and permissive to viral
gene expression and infectious virus production. Traffick-
ing of BM-derived HIV-1-infected monocytes has been
shown to be involved in the dissemination of HIV-1 into
the central nervous system (CNS), and it is possible that
HIV-1 replication in the BM and infection of BM HPCs may
be involved in the early steps leading to the development
of HIV-1-associated dementia (HAD) as an end result of
this cellular trafficking process. In addition, the growth
and development of HPCs in the BM of patients with HIV-
1 has also been shown to be impaired due to the
presence of HIV-1 proteins and changes in the cytokine
milieu, potentially leading to an altered maturation
process and to increased cell death within one or more
BM cell lineages. Changes in the growth and differenti-
ation process of HPCs may be involved in the generation
of monocyte populations that are more susceptible and/
or permissive to HIV-1, and have potentially altered
trafficking profiles to several organs, including the CNS.
A monocyte subpopulation with these features has been
shown to expand during the course of HIV-1 disease,
particularly in HAD patients, and is characterized by low
CD14 expression and the presence of cell surface CD16.
Introduction
The bone marrow (BM) is the site of hematopoiesis in humans.
The cellular components of the BM include fibroblasts, endothelial
cells, adipocytes, macrophages, osteoblasts, osteoclasts, reticular
cells, and mesenchymal stem cells (MSCs), which are collectively
called stromal cells [1], the megakaryocytes, and the hematopoi-
etic progenitor cells (HPCs) (Figure 1). HPCs consist of a
heterogeneous population of cells that includes the hematopoietic
stem cells (HSCs), which are the most primitive HPCs, capable of
producing of blood cell lineages. The loss of one or more
developmental potentials of the HSC results in an HPC committed
to any number of specific hematopoietic cell lineages. Besides the
loss of pluripotency, committed hematopoietic progenitors display
a number of characteristics that differ from their parents, including
the lack of capacity for self-renewal, a higher fraction of cells
traversing the cell cycle, and a change in their surface protein
profile [2]. HSCs are able to give rise to common lymphoid
progenitors (CLPs) and common myeloid progenitors (CMPs).
Part of lymphoid progenitor differentiation, and particularly T cell
differentiation, occurs in the thymus. CLPs are capable of
differentiating into T cells, B cells, natural killer (NK) cells, and
plasmacytoid dendritic cell progenitors [3]. T cells and NK cell
progenitors also share a common progenitor often referred to as
the T/NK cell progenitor [4]. Myeloid progenitor differentiation
occurs exclusively in the BM. The CMPs, which are also referred
to as erythromyeloid progenitors, can differentiate into either
erythroid/megakaryopoietic progenitors or granulo/monocyte
progenitors. Further differentiation leads to commitment to a
single lineage such as red blood cell, megakaryocyte, granulocyte,
and monocyte-macrophage lineage [5]. Of these cell types, only
the megakaryocyte remains in the BM following maturation and
generates platelets by fragmentation of the exvaginations of their
membrane, while all others emigrate into the blood [2].
Leukopenias and dysplasias that may affect any of the
hematopoietic lineages are commonly observed within the
population of patients with HIV-1 [6–9], even in the absence of
opportunistic infections of the BM, neoplasias, or chemothera-
peutic treatment, clearly suggesting that HIV-1 infection is
associated with dysfunction within the process of hematopoiesis
and that these alterations may very well be due to the direct effects
of infectious virus and viral proteins in the BM. Numerous studies
have reported on a number of defects within the BM progenitor
cell populations in HIV/AIDS patients [10–18], while primitive
[13] and CD34
+CD4
+ progenitor cells [11] have been shown to be
depleted in individuals with HIV-1 compared to healthy controls.
Studies with non-human primates infected with simian immuno-
deficiency virus (SIV) or simian–human immunodeficiency virus
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the suppression of myelopoiesis occurs early in the course of
retroviral disease and involves the most primitive CD34
+
progenitor cells [17,18].
Mechanisms of HIV-1-Induced Myelosuppression
Direct infection of HPCs [19–23], inability of stromal cells to
carry out their normal functions, toxic effects of HIV-1 proteins,
and changes in the cytokine milieu are the most plausible
mechanisms for the deleterious consequences of HIV-1 replication
in the BM (Figure 2). The BM stroma provides structure, cell-to-
cell interactions, and a complex network of inhibitory and
stimulatory cytokines that are crucial for the maintenance,
differentiation, and proliferation of HPCs. Changes in the BM
stromal structure have been observed in patients with HIV-1 and
are characterized by a decrease in the fibroblastic population
paralleled by an increase of macrophage-like cells [24]. Changes in
the clonogenic capacity of BM mesenchymal stem cells, which are
responsible for the generation of heterologous stromal lineages
including fibroblasts, have been shown [25] and may be
responsible for the altered cellular composition of the BM stroma.
It has also been suggested that BM microvascular endothelial cells
are involved in BM stromal impairment in individuals with HIV-1,
exhibiting a decreased capacity to respond to regulatory signals
that would normally augment blood cell production [26]. Studies
using long-term BM cultures as the in vitro equivalent of the
hematopoietic microenvironment have also suggested that BM
stroma infected with HIV-1 is unable to support uninfected
CD34
+ progenitor cell expansion and differentiation as compared
to uninfected cultures [27–29].
A number of reports have indicated that heat-inactivated HIV-1
can induce effects on progenitor cells similar to those induced by
fully infectious virus [30,31]. This observation has prompted
investigators to look further into the possible effects of individual
HIV-1 proteins on hematopoiesis. Heat-inactivated HIV-1 and
cross-linked envelope glycoprotein gp120 were shown to induce a
decrease in clonogenic capacity and induce apoptosis through a
Fas-dependent mechanism [32,33]. In contrast, an earlier study
had suggested that gp160 may induce a T cell–mediated
stimulation of HPCs that could lead to hypercellularity in the
BM [34]. Moreover, the HIV-1 Gag protein has been shown to
suppress colony formation from HPCs [35], while Vpr was shown
to induce phagocytosis of cells in the BM by mononuclear
phagocytes, possibly contributing to the failure of HPC colonies to
expand [36].
Additionally, Tat has been shown to have a role in
myelosuppression through induction of the growth inhibitory
Figure 1. Cells of the BM Susceptible to HIV-1 Infection. The cellular components of the BM include HPCs at all stages of differentiation,
megakaryocytes, fibroblasts, endothelial cells, adipocytes, macrophages, osteoblasts, osteoclasts, and MSCs, while DCs, T cells, and B cells may also
migrate from the blood into the BM. A black arrow indicates the differentiation process from one cell type to another. A dashed black line indicates
that one or more intermediate cell types have been omitted from the respective differentiation process. A red line points to cells that are known to
be infected by HIV-1. A dashed red line points to cells that have been shown to be infected by HIV-1, but the extent of their infection and their role in
HIV-1 pathogenesis is questionable.
doi:10.1371/journal.ppat.1000215.g001
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+
peripheral blood cells that were exposed to HIV-1 either in vivo
or in vitro resulted in a significant improvement in their growth
and survival, suggesting a critical role for this cytokine in this
important biological process [32]. In agreement with these results,
a more recent study reported that gp120 can lead to TGF-b1
upregulation in CD34
+ HPCs, and at the same time downregu-
lation of APRIL, a cytokine known to induce proliferation [31].
On the contrary, studies investigating TGF-b production within
the BM stroma failed to identify any differences in the absence or
presence of HIV-1 [26,30,38]. This observation points to the
inherent difficulty in examining the effect of individual proteins on
HPCs—that is, whether the extracellular concentration of HIV-1
proteins in the BM is enough to promote the same effects as
observed in vitro.
Several hematopoietic growth factors, as well as cytokines
associated with inflammation and immune activation, have been
investigated with respect to interference in HPC expansion. A role
for stem cell factor (SCF), granulocyte-macrophage-colony
stimulating factor (GM-CSF), and IL-3 has not been observed
[26,38], while an impairment in granulocyte–colony stimulating
factor (G-CSF) and IL-6 production from stromal cells has only
been shown following IL-1a stimulation [26]. IFN-a and IL-4
have been reported to be responsible for part of the HIV-1-
induced myelosuppression observed in long-term BM cultures
[29]; however, results from other studies are in disagreement with
this result [26,30]. Previous studies have reported a decrease in IL-
2 production from BM stromal cells derived from patients with
HIV-1, but a direct correlation with HPC impairment has not
been demonstrated [24,39]. The proinflammatory cytokines TNF-
a, IL-1a, and IL-6, as well as the b-chemokines MIP-1a, MIP-1b,
and RANTES, have been reported to be upregulated in the BM of
patients with HIV-1 [24,25,39], while TNF-a involvement in
HIV-1-induced suppression of hematopoiesis has been shown in
neutralization studies [30,40]. SDF-1, the natural ligand for
CXCR4, is constitutively present in the BM [41], but there are no
reports examining changes in SDF-1 expression in the BM of
patients with HIV-1. Nevertheless, SDF-1 has been shown to
regulate adhesion survival and proliferation of HPCs [42], and its
role in the HIV-1-infected BM warrants investigation, as it may be
involved in limiting infection by CXCR4-utilizing strains of HIV-
1.
HIV-1 Infection of Accessory Cells of the BM
Among the stromal cells, macrophages are the only, or the most
prominent, cell type that are productively infected with HIV-1 and
express viral antigens both in vivo [24] and in primary BM
cultures [43,44]. Importantly, macrophages in the BM were shown
to be susceptible to both macrophage tropic and T cell–tropic
strains of HIV-1, and to have a broader susceptibility to HIV-1
strains than blood-derived macrophages [44]. Consistent with the
human studies, results from SIV-infected macaques suggest that
macrophages are the primary target of SIV within the BM
compartment [45]. Eosinophils differentiated in vivo from BM
stromal cells, and BM fibroblasts, have been reported to be
permissive for HIV-1 [46,47]. However, these results have not
been confirmed by more recent reports, and contamination of the
eosinophils and fibroblast cultures with macrophages may have
contributed to the results observed in these studies. Limited
susceptibility of endothelial cells to HIV-1 has been demonstrated
in various systems, and BM microvascular endothelial cells devoid
of macrophages have been shown to be the predominant cells
infected in BM stromal cultures [26].
Megakaryocytes, as well as their precursors, express CD4 [6,48]
and CXCR4 [49,50], and several studies have shown that they are
permissive for HIV-1 infection [51–53]. Notably, in a more recent
study, in addition to CD4 and CXCR4, CCR5 was detected on
the surface of megakaryocytes, and infection of these cells with
both CCR5-tropic and CXCR4-tropic HIV-1 has been reported
[53]. It has been postulated that thrombocytopenia, which is a
very common finding in patients suffering from HIV disease, may
Figure 2. Mechanism of HIV-1-Induced Myelosuppression. Several mechanisms may be involved in HIV-1-induced impairment of
hematopoiesis. (A) HPCs may be infected by HIV-1. (B) The interaction of HIV-1 proteins with HPCs may have a direct effect on hematopoiesis. (C) HIV-
1 may indirectly affect HPCs by interacting and/or infecting BM stromal cell populations, making them unable to support normal HPC functions. (D)
HIV-1 replication in the BM may lead to changes in the cytokine milieu, which may in turn profoundly impact HPC function.
doi:10.1371/journal.ppat.1000215.g002
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productive infection, HIV-1 has been shown to negatively affect
the survival and maturation of HPCs towards megakaryocytes,
and it has been suggested that gp120–CD4 interaction may be
mediating the observed effect [31].
HIV-1 Infection of HPCs
The literature regarding susceptibility of BM stem cells and
HPCs to HIV-1 infection is extensive, and although it has been
almost 20 years since the first report of HPC infection [54], there is
still considerable controversy in this area of investigation. Early
studies have shown that CD4 is expressed in 25%–65% of CD34
+
BM cells, and these studies have estimated that the level of
expression is half of what has been observed in monocytes and
only 5% of the level reported on CD4
+ T cells [55,56]. Several
studies have confirmed these results and have also demonstrated
the presence of CXCR4 and CCR5 on these cells. The results
have been rather consistent regardless of the source of CD34
+ cells
or the state of differentiation, and whether or not mRNA or
protein levels were assessed [11,23,57–60]. The main difference
among these studies has concerned the level of CCR5 expression,
which appears to vary depending on the state of differentiation of
the progenitor cell population [23].
Despite the detection of the HIV-1 receptor and coreceptors on
HPCs, in vitro studies designed to infect these cells with HIV-1
have generated conflicting observations. The first report to
describe HIV-1 infection of HPCs was able to detect infected
cells 1 to 2 months after virus exposure, when the cells had stopped
expressing HPC markers and had become lineage-specific cells
[54]. This study, although a landmark investigation, has been
challenged with respect to the purity of the initial CD34
+ BM
culture used to establish the infected cell population [6,61]. Later
studies that demonstrated HIV-1 infection of HPCs were also
performed with mixed CD34
+ populations prepared from the BM,
which included early progenitors along with some more
differentiated and lineage-committed CD34
+ cells [19,20]. HIV-
1 infection studies performed on peripheral blood–derived CD34
+
cells generated similar results but also failed to address the purity
and differentiation state of the initial CD34
+ target cell population
[21]. To determine the major cell type in the mixed CD34
+ BM
population susceptible to HIV-1, cells were cloned in solid cultures
[22] and the presence of virus in colony-forming units (CFU) was
determined. Granulocyte-macrophage-CFU and to a lesser extent
erythroid-burst forming units were infected; however, granulcyte-
erythroid-macrophage-megacaryocyte-CFU were not, indicating
that some primitive HPCs, but not the multipotent HPCs, may be
susceptible to in vitro HIV-1 infection. When the AC133 marker
was used to purify the most primitive CD34
+ cells from cord
blood, infection with HIV-1 was not possible [62]. Similarly, the
CD38 marker has been used in some studies to define the
differentiation state of CD34
+ HPCs. CD38 is absent from the
early HPCs and appears as they differentiate, but before they start
expressing lineage-specific markers and downregulating CD34
expression [63]. Weichold et al. showed that CD34
+/CD38
+ BM
cells were susceptible to both M-tropic HIV-1 and HIV-2, but
they were not able to conclusively demonstrate infection of the
more primitive CD34
+/CD38
2 cells with either type of virus [64].
However, an additional study has reported that both CD34
+/
CD38
+ and CD34
+/CD38
2 cells were susceptible to HIV-1, and
that only the very early stem cells, which are metabolically inactive
and arrested at the G0 state, were resistant to HIV-1 [23].
Although in vitro HIV-1 infection of HPCs has been shown in a
number of studies, detection of HIV-1-infected HPCs in vivo has
only been demonstrated within a subpopulation of patients. In
1990, von Laer et al. reported that only one in 14 patient samples
of BM-derived CD34
+ cells harbored proviral DNA [65].
However, the sensitivity of the PCR assay used in this study
may be questionable since in the same study HIV-1-specific
sequences were detected within the monocytes of two of the 14
patients. However, consistent with these observations, a highly
sensitive PCR assay that was shown to detect one copy of HIV-1 in
10
3 cells was used by Davis et al. to demonstrate the presence of
proviral DNA in BM-derived CD34
+ cells in only one out of 11
patients with HIV-1 [66]. Much higher frequencies of HIV-1
infection of CD34
+ cells were reported within Zairian patients with
HIV disease (36.5%). In the same study, 14% of patients infected
with HIV-1 from the United States appeared to harbor viral
sequences in their CD34
+ cell population [67], a frequency
marginally higher than that described in earlier reports. Higher
frequencies of viral infection within the BM CD34
+ cell
compartment have been reported in more recent studies, ranging
from 20% to 28% [14,61,68], possibly reflecting an improvement
in the sensitivity of the PCR assays used. Nevertheless, when
interpreting these studies, the purity of the CD34
+ population
should be considered, given that the BM is highly vascular and it is
impossible to distinguish whether the virus is associated with
resident cells of the BM or with cells present in the vasculature.
Overall, the spectrum of in vitro and in vivo studies points to the
fact that HIV-1 infection of the HPC compartment is limited in
extent. The refractile nature of this developing immune cell
precursor population, despite the expression of CD4, CCR5, and
CXCR4, may be explained by a potential masking of the gp120
binding site. In fact, CD34
+ HPCs have been shown to secrete the
CCR5 ligands MIP-1a, MIP-1b, and RANTES [69,70], and the
CXCR4 ligand SDF-1 [60], which may compete with infectious
HIV-1, either CCR5- or CXCR4-utilizing virus, and consequently
block infection.
The difficulty in detecting HIV-1-infected HPCs in vivo may
also be due to the limited time frame during which these cells
express progenitor cell markers following their infection with HIV-
1. A number of studies suggest that the HPCs that are susceptible
to HIV-1 are not the most primitive ones and they may already be
committed to a cell lineage. Infection of megakaryocyte progen-
itors [71] and mast cell progenitors [72,73] by HIV-1 has been
demonstrated, while conditions that induce differentiation towards
dendritic cells (DCs) [74] and monocytes have been shown to
promote infection of HPCs [20,57]. Therefore, it is likely that the
HPC that gets infected with HIV-1 can only undergo a limited
number of cell divisions and is destined to promptly lose its
progenitor surface markers. Moreover, HIV-1 infection of HPCs
may promote their differentiation and decrease the time frame in
which these cells may be identified as HPCs.
Indirect evidence that HPCs infected with HIV-1 can survive and
proliferate was derived from a study where a defective HIV-1
sequence had been integrated in the genome of both CD8
+ Tc e l l s
and granulocytes. Since the provirus was unable to guide multiple
rounds of infection, it was assumed that HIV-1 infection must have
occurred in a common progenitor of CD8
+ T cells and granulocytes
[75]. However, given the very small pool of HPCs that may be
infected with HIV-1, and possibly in only a limited number of
patients, it is often implied that HIV-1 infection of HPCs is
physiologically unimportant [61,65,66]. Radically contradicting this
line of thinking, a recent study argues that even one or two infection
events of a key cell population with proliferative capacity and long-
term persistence may be a crucial obstacle for eradication. Bailey et
al. demonstrated that in some patients with HIV-1 undergoing
successful highly active antiretroviral therapy (HAART) there are
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prolonged periods of time. These sequences differ from those
commonly found in CD4
+ T cells, and do not carry any known
resistance mutations, which suggests that the rare infection of a small
number of progenitor cells is the most likely explanation for the
observed residual viremia [76].
Trafficking of HIV-1-Infected Cells to and from the
BM
The BM, in addition to its role in the generation of all
hematopoietic cell lineages, is also a primary and a secondary
lymphoid organ, and therefore is a site for the continuous
interaction of immune cells, which provides an expanded
opportunity for the dissemination of HIV-1. The role of the BM
as a secondary lymphoid organ has been emphasized by recent
evidence indicating that the BM serves as a major reservoir of
central memory T cells [77] while it also recruits naı ¨ve T cells [78]
and promotes antigen-presenting cell and T cell interaction
[79,80]. Importantly, it has been shown that CD4
+ T cells in
the blood of patients with HIV migrate to the BM at rates higher
than those in uninfected individuals, and that the enhanced
homing of these cells correlates with active HIV-1 replication [81].
Studies in the SIV-macaque model of HIV-1 infection have shown
dissemination of the virus into the BM within the first 2 weeks
following inoculation [82]. As CD4
+ T cells migrate into the BM,
they may provide a source of replicating virus and be responsible
for the initial dissemination of the virus into this anatomical
compartment. However, CD4
+ T cells are not the only possible
candidates for introduction of HIV-1 into the BM; DCs
emigrating from tissues into the peripheral circulation have been
shown to traffic to the BM, where they were retained and able to
interact with central memory T cells and trigger immune
responses [79]. Although possible, this route of DC trafficking
has not yet been shown in HIV-1 or SIV models; instead, DCs
have been shown to be infected with SIV in mucosal tissues and to
disseminate through the lymphatic circulation in the draining
lymph nodes [83,84]. In addition to cell-associated virus, cell-free
virus may also be involved in the dissemination of HIV-1 within
the BM compartment.
Once HIV-1 has established a productive infection in the BM,
opportunity for dissemination considerably increases since cells
originating from the BM, primarily monocytes, are able to travel
to all tissues. Monocytes may also emigrate from the BM
uninfected and become infected by HIV-1 during their circulation
in the blood. Considering the relative resistance of monocytes to
HIV-1, due to the expression of APOBEC3G [85], it is currently
unknown what is the relative contribution of monocyte and
monocyte progenitor infection to the pool of infected circulating
monocytes in patients with HIV-1. Lungs, gastrointestinal tract,
kidney, urogenital tract, primary and secondary lymphoid organs,
and the central nervous system (CNS) are some of the organs that
BM-derived monocytes will migrate into [86], and these
monocytes will differentiate toward tissue-specific macrophages
and DCs. Migration of HIV-1-infected monocytes into the lungs
may play an important role in the pathophysiology of pulmonary
disease [87]. Migration of infected cells of the monocyte-
macrophage lineage into the mucosal tissues of the gastrointestinal
tract or the urogenital tract is thought to play a critical role in viral
transmission [88]. However, the most profound impact of HIV-1-
infected monocyte trafficking is caused by their ability to cross the
blood–brain barrier and deliver HIV-1 into the CNS (Figure 3),
contributing not only to HIV-1-associated neurologic dysfunction
but also to the life-long persistence of HIV-1. A continuous
repopulation of macrophages, and to a lesser extent microglia,
occurs in the uninfected CNS, and has been shown to be
considerably accelerated in cases of inflammation [89]. Studies in
rodents have shown that approximately 60%, 30%, and 1% of
meningeal macrophages, perivascular macrophages, and microg-
lia, respectively, are replaced by cells originating from the BM
within a 1-month period [90]. During the repopulation of
macrophages and microglia from BM-derived monocytes, some
of which may be infected with HIV-1, the virus gains access to the
CNS. In support of this model, an elegant study has recently
reported monocyte migration into the CNS in acute SIV infection
coupled with concurrent dissemination of the virus to this
compartment [91]. Although CD4
+ T cell trafficking in the
CNS also occurs, its contribution to the dissemination of HIV-1 in
the CNS has not been characterized. Interestingly, it has been
shown that the majority of viral sequences in the cerebrospinal
fluid are generated by short-lived cells, possibly CD4
+ T cells, that
have been infected inside the CNS [92], emphasizing that CD4
+ T
cells may have a role in viral dissemination inward but also
outward of the CNS. The possibility of cell-free virus or trafficking
into the CNS has not been excluded, but is considered of lesser
importance in the pathogenesis of HIV-1-associated CNS disease
[93–96].
Two main monocyte subsets have been described, the CD14
hi/
CD16
2 monocytes, which are the most prevalent, and the
CD14
low/CD16
+ monocytes, which consist of approximately
5%–15% of circulating monocytes in healthy individuals. In a
number of pathologic conditions this monocyte population has
been shown to expand [97,98], and in patients with HIV-1, the
CD14
low/CD16
+ monocyte population may increase to as high as
40% of the total circulating monocyte population [99]. It is
unclear whether this expansion is due to the increased production
of CD14
low/CD16
+ monocytes in the BM or whether it occurs
after differentiation of the CD14
hi/CD16
2 to CD14
low/CD16
+
monocytes and represents a different state of maturation
[100,101]; in either case, this monocytic subset has been shown
to exhibit features that link it to the development of HIV-1-
associated CNS disease. Studies have shown that the CD14
low/
CD16
+ monocytes have a more activated, proinflammatory
phenotype [102], and that they are increased in patients with
HIV-1-associated dementia (HAD) more than they are in non-
demented patients with HIV-1 [103]. Recently, the CD14
low/
CD16
+ monocyte was shown to be more susceptible to HIV-1
entry and permissive to productive infection [104]. These cells are
thought to migrate more effectively to the CNS than the classical
CD14
hi/CD16
2 monocytes and have been shown to accumulate
in perivascular regions of the brain, where they have also been
shown to colocalize with HIV-1-specific proteins [105,106].
Currently, there are no definitive direct observations demon-
strating that the monocytes migrating to the brain have been
infected with HIV-1 while they were in the BM, potentially as
monocyte progenitors, or whether infection occurred while in the
blood. However, HIV-1-specific sequences from the BM resemble
sequences from the deep white matter of the brain more than any
other tissue, suggesting direct HIV-1 trafficking from the BM into
the CNS [107], at least during the later stages of HIV-1 disease.
However, it is possible that HIV-1 infection in the BM, which
causes changes in the cytokine milieu as previously described,
impacts the maturation of HPCs towards the monocytic lineage,
resulting in the generation of a monocyte subset that is more prone
to migration into tissues and specifically into the CNS. This
monocyte subset, possibly represented by the CD14
low/CD16
+
phenotype, is more susceptible to infection and becomes infected
by HIV-1 before it leaves the BM or shortly thereafter, thus
PLoS Pathogens | www.plospathogens.org 5 December 2008 | Volume 4 | Issue 12 | e1000215Figure 3. Trafficking of HIV-1-Infected Cells from the BM to the CNS. Monocytes infected in the BM with HIV-1 either as HPCs or as
commited monocyte progenitors emigrate from the BM into the blood, and through the blood circulation reach the capillary vessels of the brain,
where they may cross the blood–brain barrier and migrate into the CNS. Following entry into the CNS, monocytes differentiate into perivascular
macrophages, which has been shown to typically lead to upregulation of viral protein production, release of virions, and infection of resident cells of
the CNS.
doi:10.1371/journal.ppat.1000215.g003
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well as thrombocytopenia [109], has been shown to correlate
tightly with the development of HAD, suggesting that HIV-1-
induced pathogenesis of the BM may impact HAD progression.
Similarly, a recent report showing that BM diffusion rates
correlate with dementia severity [110] provides additional support
for the hypothesis that events in the BM may be associated with
the development of HAD [95].
Conclusions
The central role of the BM in the pathogenesis of HIV-1 is
highlighted by the wide spectrum of hematopoietic abnormalities
observed in patients with HIV-1. It is has been questioned whether
any of these abnormalities are due to direct HIV-1 infection of
HPCs; however, collectively the data suggest that the presence and
replication of HIV-1 in the BM impact either directly or indirectly
the normal proliferation and differentiation of HPCs, resulting in
changes in the cell populations of the blood. The effect on the
generated monocytes may not be solely in numbers but also in
their migratory properties and in their susceptibility to HIV-1,
ultimately impacting the pathogenesis of AIDS and HAD.
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